Estrela Daniel, Santos Rita F, Masserdotti Alice, Silini Antonietta, Parolini Ornella, Pinto Inês Mendes, Cruz Andrea
International Iberian Nanotechnology Laboratory (INL), 4715-330 Braga, Portugal.
Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal.
Biomolecules. 2025 Feb 20;15(3):312. doi: 10.3390/biom15030312.
Molecular biomarker profiling is an emerging field in maternal-fetal health with the potential to transform early detection and prediction of placental dysfunction. By analysing a range of biomarkers in maternal blood, researchers and clinicians can gain crucial insights into placental health, enabling timely interventions to enhance fetal and maternal outcomes. Placental structural function is vital for fetal growth and development, and disruptions can lead to serious pregnancy complications like preeclampsia. While conventional methods such as ultrasound and Doppler velocimetry offer valuable information on fetal growth and blood flow, they have limitations in predicting placental dysfunction before clinical signs manifest. In contrast, molecular biomarker profiling can provide a more comprehensive assessment by measuring proteins, metabolites, and microRNAs (miRNAs) in maternal blood, reflecting the placenta's endocrine and metabolic functions. This approach offers a deeper understanding of placental health and function, aiding in early detection and prediction of complications. Challenges in developing molecular biomarker profiling include pinpointing specific molecular changes in the placenta linked to pathologies, timing predictions of conditions before clinical onset, and understanding how placental dysfunction affects maternal metabolism. Validating specific biomarkers and integrating them effectively into clinical practice requires further research. This review underscores the significance of molecular biomarker profiling as a powerful tool for early detection and prediction of placental dysfunction in maternal-fetal health. Through an exploration of biomarker analysis, we delve into how a deeper understanding of placental health can potentially improve outcomes for both mother and baby. Furthermore, we address the critical need to validate the utility of biomarkers and effectively integrate them into clinical practice.
分子生物标志物分析是母胎健康领域中一个新兴的研究方向,具有改变胎盘功能障碍早期检测和预测的潜力。通过分析母体血液中的一系列生物标志物,研究人员和临床医生能够深入了解胎盘健康状况,从而及时进行干预,改善胎儿和母体的结局。胎盘的结构功能对胎儿的生长发育至关重要,其功能紊乱可能导致严重的妊娠并发症,如先兆子痫。虽然超声和多普勒测速等传统方法能提供有关胎儿生长和血流的有价值信息,但在临床症状出现之前,它们在预测胎盘功能障碍方面存在局限性。相比之下,分子生物标志物分析可以通过测量母体血液中的蛋白质、代谢物和微小RNA(miRNA),提供更全面的评估,反映胎盘的内分泌和代谢功能。这种方法有助于更深入地了解胎盘的健康和功能,辅助早期检测和并发症预测。开发分子生物标志物分析面临的挑战包括确定与胎盘病理相关的特定分子变化、在临床发病前对病情进行预测以及了解胎盘功能障碍如何影响母体代谢。验证特定生物标志物并将其有效整合到临床实践中还需要进一步研究。本综述强调了分子生物标志物分析作为母胎健康中胎盘功能障碍早期检测和预测的有力工具的重要性。通过对生物标志物分析的探讨,我们深入研究了如何更深入地了解胎盘健康状况,从而有可能改善母婴结局。此外,我们还讨论了验证生物标志物效用并将其有效整合到临床实践中的迫切需求。